EICHOR
● Active Not Recruiting
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Condition: Non Small Cell Lung Cancer (Stage III) · Sponsor: AstraZeneca
About this study
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (118)
| Research Site | Duarte, California, United States | — |
| Research Site | Atlanta, Georgia, United States | — |
| Research Site | Florham Park, New Jersey, United States | — |
| Research Site | Salt Lake City, Utah, United States | — |
| Research Site | Madison, Wisconsin, United States | — |
| Research Site | Ciudad Autónoma de Bs. As., Argentina | — |
| Research Site | Ciudad Autónoma de Bs. As., Argentina | — |
| Research Site | Mar del Plata, Argentina | — |
| Research Site | Rosario, Argentina | — |
| Research Site | San Salvador de Jujuy, Argentina | — |
| Research Site | Barretos, Brazil | — |
| Research Site | Curitiba, Brazil | — |
+ 106 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03521154